NKP-1339
Tier C — Watch / tradeNKP-1339
Targets：p38 MAPK, GRP78
Indications (approved)：Bile duct cancer, Cholangiocarcinoma, Colorectal cancer, Gastric cancer, Pancreatic cancer, Sarcoma, Solid tumour
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| - | 271-44-3 | 1H-indazole |
| - | 124875-20-3 | - |
Frequently asked questions
What are the approved indications of NKP-1339?
Approved indications include: Bile duct cancer, Cholangiocarcinoma, Colorectal cancer, Gastric cancer, Pancreatic cancer, Sarcoma, Solid tumour.
When does the NKP-1339 patent expire?
No public expiry year is available for NKP-1339 yet; this page updates once verified.
How many synthesis routes are recorded for NKP-1339?
1 synthesis routes are recorded; the shortest is 2 steps with 118 mg total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy NKP-1339 intermediates?
All intermediates in NKP-1339 routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for NKP-1339 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21